Amarin Corporation plc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Amarin Corporation plc |
Stock Symbol : | NASDAQ: AMRN |
Class Period Start: | 09/24/2018 |
Class Period End: | 11/08/2018 |
Lead Plaintiff motion: | 04/23/2019 |
Date Filed: | 02/22/2019 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the District of New Jersey |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the April 23, 2019 lead plaintiff deadline in a class action lawsuit filed against Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Amarin Corporation plc securities between September 24, 2018 and November 8, 2018, have until April 23, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Amarin Corporation plc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the top-line results Amarin touted concerning its REDUCE-IT trial for Vascepa, a drug intended to treat cardiovascular disease, were not as positive as Amarin had represented; the placebo given to patients in the control arm of the REDUCE-IT trial may have increased the rate of cardiovascular events in those patients; and as a result, Amarin’s public statements were materially false and misleading at all relevant times. On November 12, 2018, an article was published on Seeking Alpha about Amarin’s “recent revelations of positive topline results” from its REDUCE-IT trial for Vascepa claimed that “the placebo group received an active agent that in effect was an anti-statin,” and that the REDUCE-IT trial results may have consequently exaggerated the efficacy of Vascepa. Following this news, NASDAQ: AMRN dropped 22%, to close at $15.38 on November 13, 2018. If you were negatively impacted by your investment in Amarin Corporation plc securities between September 24, 2018 and November 8, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |